Laquinimod effects on MRI activity: results of a 36-week extension study


REPORT FROM THE ENS 2008Laquinimod, a novel immunomodulatory agent in clinical development, significantly reduces the number of gadolinium-enhancing lesions on MRI, according to the results of a phase II extension study (Comi et al. Abstract 0193. J Neurol 2008;255(suppl 2): 46).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page